Accession Number: | 0001209191-19-059277 |
Date: | 2019-12-03 |
Issuer: | CRISPR THERAPEUTICS AG (CRSP) |
Original Submission Date: |
HO TONY W
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE, MA 02139
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2019-12-03 | deemed execution date | A | 40,000 (a) | common shares 40,000 | $0.00 | 40,000 | direct |
ID | footnote |
---|---|
f1 | each restricted stock unit represents a contingent right to receive one share of crsp common shares. |
f2 | the restricted stock units shall vest as follows: two-thirds of the grant shall vest on december 3, 2021 and the remaining one-third shall vest on december 3, 2022 |